Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexios Matikas

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Oncoimmunology|September 20, 2018
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancerAlexios Matikas, John Lövrot, Anna Ramberg, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|March 5, 2025
Ensuring Model Fairness via Stratified Training: TP53 Mutation Prediction with Estrogen Receptor Stratification in Breast HistopathologyNikos Tsiknakis, Kang Wang, Dimitrios Salgkamis, et al.
Cancers|September 28, 2021
Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast CancerIoannis Zerdes, Vaia Karafousia, Artur Mezheyeuski, et al.
The Lancet Regional Health. Europe|October 13, 2025
Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based studyXingrong Liu, Behnaz Binicy, Balazs Acs, et al.
Targeted Oncology|June 17, 2019
MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal CancerAlexios Matikas, John Souglakos, Panagiotis Katsaounis, et al.
Acta Oncologica (Stockholm, Sweden)|October 5, 2019
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancerAntroula Papakonstantinou, Elham Hedayati, Mats Hellström, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2026
Integrating liquid biopsies and artificial intelligence for early cancer detection: A systematic review and meta-analysisPanagiotis Filis, Georgios Markozannes, Dimitrios Salgkamis, et al.
The Lancet Regional Health. Europe|December 20, 2024
Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trialAlexios Matikas, Andri Papakonstantinou, Sibylle Loibl, et al.
Cancers|June 10, 2022
Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter StudyUna Kjällquist, Balazs Acs, Sara Margolin, et al.
Journal of Internal Medicine|February 14, 2026
Perioperative immune checkpoint inhibitor therapy across tumors: Insights and shared lessons from a rapidly evolving fieldKarl Björkström, Alexios Matikas, Fernanda Costa Svedman, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Oncoimmunology|September 20, 2018
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancerAlexios Matikas, John Lövrot, Anna Ramberg, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|March 5, 2025
Ensuring Model Fairness via Stratified Training: TP53 Mutation Prediction with Estrogen Receptor Stratification in Breast HistopathologyNikos Tsiknakis, Kang Wang, Dimitrios Salgkamis, et al.
Cancers|September 28, 2021
Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast CancerIoannis Zerdes, Vaia Karafousia, Artur Mezheyeuski, et al.
The Lancet Regional Health. Europe|October 13, 2025
Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based studyXingrong Liu, Behnaz Binicy, Balazs Acs, et al.
Targeted Oncology|June 17, 2019
MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal CancerAlexios Matikas, John Souglakos, Panagiotis Katsaounis, et al.
Acta Oncologica (Stockholm, Sweden)|October 5, 2019
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancerAntroula Papakonstantinou, Elham Hedayati, Mats Hellström, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2026
Integrating liquid biopsies and artificial intelligence for early cancer detection: A systematic review and meta-analysisPanagiotis Filis, Georgios Markozannes, Dimitrios Salgkamis, et al.
The Lancet Regional Health. Europe|December 20, 2024
Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trialAlexios Matikas, Andri Papakonstantinou, Sibylle Loibl, et al.
Cancers|June 10, 2022
Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter StudyUna Kjällquist, Balazs Acs, Sara Margolin, et al.
Journal of Internal Medicine|February 14, 2026
Perioperative immune checkpoint inhibitor therapy across tumors: Insights and shared lessons from a rapidly evolving fieldKarl Björkström, Alexios Matikas, Fernanda Costa Svedman, et al.
Pageof 10